Angiodynamics (ANGO) EBT (2010 - 2026)

Angiodynamics (ANGO) has reported EBT for 17 consecutive years, with -$11.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 80.61% year-over-year to -$11.0 million; the trailing twelve-month figure through May 2026 stood at -$36.3 million (down 6.66% YoY), and the FY2026 full-year result was -$36.3 million, down 6.66% from the prior year.
• EBT retreated to -$11.0 million in Q2 2026 per ANGO's latest filing, from -$8.1 million in the prior quarter.
• Across five years, EBT topped out at $34.9 million in Q3 2023 and bottomed at -$199.7 million in Q1 2024.
• Historically, EBT has averaged -$18.3 million across 5 years, with a median of -$10.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: EBT soared 351.58% in 2023, then slumped 1966.85% in 2024.
• Over 5 years, EBT stood at -$9.1 million in 2022, then sank by 39.41% to -$12.6 million in 2023, then rose by 14.03% to -$10.8 million in 2024, then surged by 41.42% to -$6.4 million in 2025, then sank by 73.64% to -$11.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$11.0 million, -$8.1 million, and -$6.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.